Hosted on MSN
Implantable cardioverter defibrillators did not improve mortality in selected heart-attack patients
Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and ...
Prophylactic, substrate-guided ablation of LV scars reduced the risk for subsequent VT in patients with ICDs for post-MI arrhythmias. Implantable cardioverter-defibrillator (ICD) therapy reduces ...
An extravascular ICD with a substernal lead might retain the benefits, and avoid the risks, of transvenous and subcutaneous ICDs, but data on safety and efficacy are needed. New research findings are ...
KIRKLAND, Wash.--(BUSINESS WIRE)--Kestra ™ Medical Technologies, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) Premarket Approval for the ASSURE ® Wearable ...
Medical Device Network on MSN
AtaCor raises $75m for trial of EV-ICD system
AtaCor Medical has raised $75m financing to support a study of its extravascular implantable cardioverter-defibrillator ...
Additional Health Plans Contract with Kestra Medical Technology Services, Inc., increasing patient access to the ASSURE system as a covered service. KIRKLAND, Wash.--(BUSINESS WIRE)--Kestra Medical ...
Please provide your email address to receive an email when new articles are posted on . Reducing the current 6-month driving restriction following a new implantable cardioverter defibrillator to 3 ...
Element Science acquired a CE mark in Europe and a green light in the U.K. for its patch-based cardioverter defibrillator, designed to provide an easier-to-wear device for people in danger of sudden ...
Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback